A 28-year-old male presents with acute-onset muscle paralysis, autonomic instability, and respiratory compromise following a Campylobacter jejuni gastroenteritis 2 weeks prior. Lumbar puncture shows elevated protein with normal cell count. Which investigation is most appropriate to confirm the diagnosis of Guillain–Barré syndrome?

Explanation

## Investigation of Choice for Guillain–Barré Syndrome ### Pathophysiology of GBS Guillain–Barré syndrome is an acute autoimmune polyradiculoneuropathy affecting peripheral nerves and nerve roots. The disease is triggered by molecular mimicry following infections (Campylobacter jejuni is the most common), leading to antibody-mediated demyelination and axonal degeneration at the neuromuscular junction and peripheral nerves. ### Why Nerve Conduction Studies & EMG? **Key Point:** Nerve conduction studies (NCS) and electromyography (EMG) are the **gold standard diagnostic investigations** for GBS because they directly demonstrate the pathophysiology: demyelination (slowed conduction velocity, prolonged latencies, conduction blocks) and/or axonal degeneration (reduced amplitude). **High-Yield:** NCS/EMG findings in GBS: - **Demyelinating pattern:** Slowed conduction velocity, prolonged distal latencies, conduction blocks, prolonged F-wave latencies - **Axonal pattern:** Reduced compound muscle action potential (CMAP) amplitude, reduced sensory nerve action potential (SNAP) amplitude - **Sensitivity:** 80–90% in the first 2 weeks; increases with disease progression - **Specificity:** High when combined with clinical presentation ### Diagnostic Algorithm for GBS ```mermaid flowchart TD A[Acute ascending paralysis + areflexia]:::outcome --> B[Lumbar puncture:<br/>Albuminocytologic dissociation]:::action B --> C{Elevated protein,<br/>normal/low cells?}:::decision C -->|Yes| D[Nerve conduction studies<br/>& Electromyography]:::action C -->|No| E[Consider alternative diagnosis]:::action D --> F{Demyelinating or<br/>axonal pattern?}:::decision F -->|Yes| G[GBS confirmed]:::outcome F -->|No| H[Repeat NCS/EMG<br/>or reconsider diagnosis]:::action ``` ### Comparison of Investigations in GBS | Investigation | Sensitivity | Specificity | Diagnostic Value | Timing | |---|---|---|---|---| | **NCS/EMG** | 80–90% | High | Gold standard; confirms demyelination or axonal injury | Days 3–7 onward | | **CSF analysis** | 90% (albuminocytologic dissociation) | Moderate | Supportive; not diagnostic alone | First week | | **Anti-ganglioside antibodies** | 50–60% | Moderate | Supports diagnosis; identifies subtype (AMAN, AMSAN) | Variable; not required | | **MRI spinal cord** | Variable | Low | Rules out compressive myelopathy; not diagnostic for GBS | Not first-line | **Clinical Pearl:** Albuminocytologic dissociation (elevated CSF protein with normal/low cell count) is characteristic but NOT diagnostic of GBS—it is merely supportive. NCS/EMG provides the definitive neurophysiological confirmation. ### Why Each Investigation Fits Its Role **NCS/EMG:** Directly demonstrates the underlying pathology (demyelination or axonal loss) with high sensitivity and specificity. This is the **confirmatory investigation of choice**. **CSF Analysis:** Supportive but non-specific. Elevated protein occurs in many conditions. The albuminocytologic dissociation is classic but not pathognomonic. **Anti-ganglioside Antibodies:** Present in only 50–60% of GBS cases. Useful for identifying subtypes (anti-GM1 in AMAN, anti-GQ1b in Miller Fisher variant) but not required for diagnosis and have lower sensitivity than NCS/EMG. **MRI Spinal Cord:** Used to exclude structural lesions (cord compression, myelitis) but does not confirm GBS. Not first-line. **Key Point:** The **combination of clinical presentation + albuminocytologic dissociation + abnormal NCS/EMG** confirms GBS with high confidence.